CN110003104A - 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 - Google Patents

水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 Download PDF

Info

Publication number
CN110003104A
CN110003104A CN201910222566.1A CN201910222566A CN110003104A CN 110003104 A CN110003104 A CN 110003104A CN 201910222566 A CN201910222566 A CN 201910222566A CN 110003104 A CN110003104 A CN 110003104A
Authority
CN
China
Prior art keywords
alkyl
compound
cancer
alkoxy
stat3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910222566.1A
Other languages
English (en)
Chinese (zh)
Inventor
梅利莎·L·菲谢尔
帕特里克·托马斯·贡宁
西纳·哈夫特舍纳里
布伦特·戴维·乔治·帕盖
塞谬尔·韦斯
赫马·阿蒂·卢奇曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uti Partners Ltd
University of Toronto
Indiana University Research and Technology Corp
Original Assignee
Uti Partners Ltd
University of Toronto
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uti Partners Ltd, University of Toronto, Indiana University Research and Technology Corp filed Critical Uti Partners Ltd
Publication of CN110003104A publication Critical patent/CN110003104A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
CN201910222566.1A 2012-05-25 2013-05-24 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 Pending CN110003104A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651757P 2012-05-25 2012-05-25
US61/651,757 2012-05-25
CN201380038486.1A CN105120854B (zh) 2012-05-25 2013-05-24 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380038486.1A Division CN105120854B (zh) 2012-05-25 2013-05-24 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法

Publications (1)

Publication Number Publication Date
CN110003104A true CN110003104A (zh) 2019-07-12

Family

ID=49624538

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910222566.1A Pending CN110003104A (zh) 2012-05-25 2013-05-24 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法
CN201380038486.1A Expired - Fee Related CN105120854B (zh) 2012-05-25 2013-05-24 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380038486.1A Expired - Fee Related CN105120854B (zh) 2012-05-25 2013-05-24 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法

Country Status (9)

Country Link
US (3) US9650399B2 (enExample)
EP (1) EP2854819B1 (enExample)
JP (2) JP6290871B2 (enExample)
CN (2) CN110003104A (enExample)
BR (1) BR112014029439A2 (enExample)
CA (1) CA2874057A1 (enExample)
HK (1) HK1218709A1 (enExample)
RU (1) RU2641903C2 (enExample)
WO (1) WO2013177534A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6570512B2 (ja) * 2013-03-22 2019-09-04 ユニバーシティ・オブ・ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 新規なＳｔａｔ３阻害剤
WO2015179956A1 (en) * 2014-05-30 2015-12-03 The Governing Council Of The University Of Toronto Sulfonamide compounds and their use as stat5 inhibitors
EP3570836A4 (en) * 2017-01-23 2020-08-19 The University of Hawaii 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE STAT3 INHIBITORS
CN113661158A (zh) * 2018-12-21 2021-11-16 多伦多大学管理委员会 新型水杨酸衍生物、其药学上可接受的盐、其组合物及其使用方法
KR102980990B1 (ko) 2019-04-05 2026-06-25 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
CN115551496A (zh) * 2020-03-05 2022-12-30 詹皮克斯有限公司 Stat抑制性化合物和组合物
JP2023515236A (ja) * 2020-03-05 2023-04-12 ジャンピックス，エルティーディ． α置換されたＳＴＡＴ阻害剤およびその組成物
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN112941036B (zh) * 2021-02-08 2023-06-09 吉林惠康生物药业有限公司 一种提高狂犬病毒在人二倍体细胞中复制水平的方法
CN114751927B (zh) * 2022-03-08 2023-10-31 中山大学 一种硼酸化合物、制备方法及用途
CN118994047B (zh) * 2024-08-13 2026-02-10 中国药科大学 一种水杨醛衍生物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117438A2 (en) * 2009-04-06 2010-10-14 University Of Central Florida Research Foundation, Inc. Compounds that suppress cancer cells and exhibit antitumor activity
WO2012018868A1 (en) * 2010-08-02 2012-02-09 University Of Central Florida Research Foundation, Inc. Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487156B1 (en) * 2003-12-11 2014-07-16 Board Of Regents The University Of Texas System Compounds for treatment of cell proliferative diseases
WO2007115269A2 (en) * 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
WO2007136858A2 (en) 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
NZ590355A (en) * 2008-07-10 2013-01-25 Yakult Honsha Kk Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
JP6570512B2 (ja) * 2013-03-22 2019-09-04 ユニバーシティ・オブ・ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ 新規なＳｔａｔ３阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117438A2 (en) * 2009-04-06 2010-10-14 University Of Central Florida Research Foundation, Inc. Compounds that suppress cancer cells and exhibit antitumor activity
WO2012018868A1 (en) * 2010-08-02 2012-02-09 University Of Central Florida Research Foundation, Inc. Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRENT D. G. PAGE等: "Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
BRENT D. G. PAGE等: "Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
STEVEN FLETCHER等: "Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules", 《CHEMMEDCHEM》 *
STEVEN FLETCHER等: "Disruption of Transcriptionally Active Stat3 Dimers with Nonphosphorylated, Salicylic Acid-Based Small Molecules : Potent in vitro and Tumor Cell Activities", 《CHEMBIOCHEM》 *
STEVEN FLETCHER等: "Mild, efficient and rapid O-debenzylation ofortho -substituted phenols with trifluoroacetic acid", 《TETRAHEDRON LETTERS》 *

Also Published As

Publication number Publication date
JP6290871B2 (ja) 2018-03-07
EP2854819B1 (en) 2020-01-15
CN105120854B (zh) 2019-04-09
BR112014029439A2 (pt) 2017-06-27
EP2854819A4 (en) 2016-06-15
RU2014152697A (ru) 2016-07-20
US20190382422A1 (en) 2019-12-19
HK1218709A1 (zh) 2017-03-10
US20150158894A1 (en) 2015-06-11
JP2018109017A (ja) 2018-07-12
CN105120854A (zh) 2015-12-02
RU2641903C2 (ru) 2018-01-23
WO2013177534A2 (en) 2013-11-28
US20170267704A1 (en) 2017-09-21
WO2013177534A3 (en) 2015-05-28
EP2854819A2 (en) 2015-04-08
JP6543366B2 (ja) 2019-07-10
CA2874057A1 (en) 2013-11-28
US9650399B2 (en) 2017-05-16
US10377780B2 (en) 2019-08-13
JP2015522551A (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
JP6543366B2 (ja) 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法
AU2014290368B2 (en) Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
CN103547152A (zh) 溴结构域蛋白的抑制剂作为基因表达的调节剂
US10954258B2 (en) STAT3 dimerization inhibitors
KR20130121818A (ko) Stat 단백질의 저해제로서의 치환된 2-히드록시-4-(2-(페닐설폰아미도)아세트아미도)벤조산 유사체
BR112019019868A2 (pt) derivados de tetra-hidro-benzo[d]azepina como moduladores gpr120
AU2014290363A1 (en) Methods and compositions for treatment of fibrosis
JP2015533778A (ja) がんの治療のための新規フェニル−ピリジン／ピラジンアミド
US8895746B2 (en) Compounds that suppress cancer cells and exhibit antitumor activity
US20220089531A1 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US20210332046A1 (en) Nicotinic acetylcholine receptor silent agonists
WO2018189679A1 (en) Isoindoline derivatives for use as ampk activators
WO2021143923A1 (zh) 硼酸衍生物
WO2025146650A1 (en) Modulators of intracellular chloride concentration
WO2024099403A1 (zh) 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2026086905A1 (zh) 一种作为钠通道调节剂的化合物的前药及其用途
TW201536775A (zh) 苯并噻吩化合物
PL243517B1 (pl) Pochodne (benzyloksy)benzenu nadające się do stosowania w immunoterapii nowotworów oraz zawierająca je kompozycja farmaceutyczna

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190712